Solace Therapeutics CEO Bill Gruber hopes to repeat the successful exit he helped execute when Hologic paid close to $300 million for his previous company Interlace.
President and CEO
Bill Gruber is currently the President and CEO of Solace Therapeutics, a startup company in the female urinary incontinence field. Bill was the President and CEO of Interlace Medical. While at Interlace he raised over $28MM in venture capital for the development and launch of devices for the treatment of Abnormal Uterine Bleeding caused by fibroids. The company was purchased by Hologic in 2011. Bill has extensive experience in venture capital fundraising, organizational development, product development and commercialization for rapid growth businesses. Before joining Interlace Medical, he spent five years at Cortek Inc., a spinal products company. As Cortek’s V.P. of Sales and Marketing, he built sales from $612K to over $10M. During his last two years, he was the V.P. of New Business Development and Marketing where he was instrumental in creating Soteira, a Cortek subsidiary, which focused on devices for treating vertebral compression fractures. Earlier in his career, Bill spent ten years at Boston Scientific Corporation, concluding his career at BSC as Director of the $172M Global Atherosclerotic Therapy business. Bill began his career in sales and marketing roles at Procter and Gamble before transitioning into the medical device sector.
Meet Our Host
Geoff has been in medtech for over two decades in both operational and investment roles. He is passionate about the industry potential and sharing stories from the front lines of innovation.